Press Release
Press Release
Reminder: Cabozantinib to be Featured in Nine Presentations at the 2013 ASCO Annual Meeting
--
The full roster of cabozantinib data presentations expected at the meeting (all times Central Daylight Time):
Oral Presentation
-
Abstract 6000: “Efficacy of cabozantinib (
Cabo ) in medullary thyroid cancer (MTC) patients with RAS or RET mutations: Results from a phase III study.”
Dr.Steven I. Sherman ,The University of Texas MD Anderson Cancer Center ,Houston, TX
Oral Abstract Session: Head/Neck CancerSunday, June 2 ,8:00-8:15 a.m. , Room E354a
Poster Discussion Presentations
-
Abstract 5026: “An exploratory analysis of bone scan lesion area
(BSLA), circulating tumor cell (CTC) change, pain reduction, and
overall survival (OS) in patients (pts) with castration-resistant
prostate cancer (CRPC) treated with cabozantinib (cabo): Updated
results of a phase II nonrandomized expansion (NRE) cohort.”
Dr.Howard I. Scher ,Memorial Sloan-Kettering Cancer Center ,New York, NY
Poster Discussion Session: Genitourinary (Prostate) CancerSaturday, June 1 ,8:00 a.m. – noon (poster display, Room E450a); 12:00 –1:00 p.m. (discussion,E Arie Crown Theater )
General Poster Presentations
-
Abstract 6090: “Long-term disease control of ≥2 years achieved with
cabozantinib in subjects with metastatic medullary thyroid carcinoma
on a phase I study.”
Dr.Ezra Cohen ,The University of Chicago Medicine ,Chicago, IL
General Poster Session: Head/Neck CancerSaturday, June 1 ,8:00-11:45 a.m. , S Hall A2
-
Abstract 9094: “Activity of cabozantinib in metastatic uveal melanoma:
Updated results from a phase II randomized discontinuation trial
(RDT).”
Dr.Adil Daud , UCSF,San Francisco, CA
General Poster Session: Melanoma/Skin CancersSaturday, June 1 ,8:00-11:45 a.m. , S Hall A2
-
Abstract 5073: “Post-treatment alterations in 18F-dihydrotestosterone
(FDHT) and FDG PET/CT in metastatic castration-resistant prostate
cancer (mCRPC) treated with cabozantinib.”
Dr.Josef J. Fox ,Memorial Sloan-Kettering Cancer Center ,New York, NY
General Poster Session: Genitourinary (Prostate) CancerMonday, June 3 ,8:00-11:45 a.m. , S Hall A2
-
Abstract TPS5094: “A phase II trial of cabozantinib (
Cabo ) in patients (pts) with castrate-resistant prostate cancer (CRPC) metastatic to bone (NCT01428219).” [Note: This is an Investigator-Sponsored Trial.]
Dr.Petros Grivas ,University of Michigan Comprehensive Cancer Center ,Ann Arbor, MI
General Poster Session: Genitourinary Cancers (Trials inProgress subsession)Monday, June 3 ,8:00-11:45 a.m. , S Hall A2
-
Abstract TPS4589: “A phase II study of cabozantinib (XL184) in
patients with advanced/metastatic urothelial carcinoma.”
[Note: This is a study conducted by the National Cancer Institute’s Cancer Therapy Evaluation Program (NCI-CTEP).]
Dr.Andrea Apolo ,Center for Cancer Research ,National Cancer Institute ,Bethesda, MD
General Poster Session: Genitourinary (Nonprostate) Cancer (Trials inProgress subsession)Monday, June 3 ,8:00-11:45 a.m. , S Hall A2
-
Abstract TPS5095: “A phase I study of cabozantinib (
Cabo ) plus docetaxel (D) and prednisone (P) in metastatic castrate resistant prostate cancer (mCRPC).”
[Note: This is an NCI-CTEP study.]
Dr.Fatima Karzai ,Center for Cancer Research ,National Cancer Institute ,Bethesda, MD
General Poster Session: Genitourinary (Prostate) Cancer (Trials inProgress subsession)Monday, June 3 ,8:00-11:45 a.m. , S Hall A2
-
Abstract 4543: “Preclinical and correlative studies of cabozantinib
(XL184) in urothelial cancer (UC).”
[Note: These are NCI-CTEP studies.]
Dr.Andrea Apolo ,Center for Cancer Research ,National Cancer Institute ,Bethesda, MD
General Poster Session: Genitourinary (Nonprostate) CancerMonday, June 3 ,8:00-11:45 a.m. , S Hall A2
Details on
The 2013 ASCO Annual Meeting abstracts featuring cabozantinib will be
posted publicly on www.asco.org
today,
Investor Briefing at the 2013 ASCO Annual Meeting
An archived replay of the webcast will be available on the Event
Calendar page under Investors & Media at www.exelixis.com
and audio-only via phone until
About
Source:
Exelixis, Inc.
Charles Butler, (650) 837-7277
Vice President,
Investor Relations and Corporate Communications
cbutler@exelixis.com